<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134630">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095379</url>
  </required_header>
  <id_info>
    <org_study_id>2014-02-055</org_study_id>
    <nct_id>NCT02095379</nct_id>
  </id_info>
  <brief_title>Oligosecretary Myeloma: Prevalence and Its Clinical Significance</brief_title>
  <official_title>Oligosecretary Myeloma: Prevalence and Its Clinical Significance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to investigate the prevalence and clinical course of
      oligosecretary myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oligosecretary myeloma is a subgroup of multiple myeloma (MM) characterized by low levels of
      serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M
      protein ≥ 1g/dL, a urine M protein ≥ 200mg/day). Patients with oligosecretary myeloma do not
      have established methods for disease monitoring and clinical informations regarding
      oligosecretary myeloma are still largely unknown.

      In this study, we aimed to investigate the prevalence and clinical course of oligosecretary
      myeloma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Number of patients with oligosecretary myeloma among multiple myeloma patients</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">390</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>oligosecretary</arm_group_label>
    <description>Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oligosecretary</intervention_name>
    <description>not abvailable</description>
    <arm_group_label>oligosecretary</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine
        monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL,
        a urine M protein ≥ 200mg/day)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine
             monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥
             1g/dL, a urine M protein ≥ 200mg/day)

          -  available clinical data

        Exclusion Criteria:

          -  patients without available clinical data
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kihyun Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Kihyun Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>oligosecretary multiple myeloma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
